Oral PCSK9 Inhibitor Poised to Transform Cholesterol Management

A new oral medication, enlicitide decanoate, developed by Merck & Co., is set to revolutionize cholesterol management by providing significant reductions in low-density lipoprotein cholesterol (LDL-C) for patients with hyperlipidemia. Dr. Ann Marie Navar, an associate professor of medicine specializing in cardiology at UT Southwestern Medical School, highlighted the implications of this promising treatment during a recent discussion on the CORALreef Lipids study (NCT05952856). If approved, enlicitide could be the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor available for cholesterol reduction.

Current treatments for high cholesterol primarily rely on statins, which are considered first-line therapy. Despite their effectiveness, many patients struggle to reach their LDL-C targets. Dr. Navar pointed out that nearly 60% of patients on high-intensity statin therapy still do not achieve these goals, highlighting the necessity for additional non-statin options. An oral PCSK9 inhibitor may help to alleviate clinical inertia and encourage prescribers who might hesitate to use injectable treatments.

Impact on Pharmacists and Patient Care

The introduction of an oral PCSK9 inhibitor like enlicitide is expected to significantly impact the role of pharmacists in patient care. Pharmacists will be crucial in counseling patients on effective administration, which involves taking the medication first thing in the morning on an empty stomach. Additionally, they will play a vital role in routine LDL-C monitoring to identify candidates for this new therapy.

Dr. Navar emphasized the importance of this proactive approach, stating, “The most important step in LDL-C control is for patients to have their LDL-C levels routinely measured. We can’t fix what we don’t measure.” Once enlicitide becomes available, pharmacists will be instrumental in ensuring that patients understand the correct way to take the medication, similar to how they currently educate patients on the administration of levothyroxine sodium.

Expected Advantages and Future Research

The shift from injectable PCSK9 inhibitors to an oral option presents both advantages and challenges for healthcare providers. Dr. Navar expressed optimism that the simplicity of an oral medication will increase clinician comfort and acceptance, potentially leading to higher rates of prescribing. Current uptake of injectable monoclonal antibodies has been low, with many primary care providers and even a significant number of cardiologists never having prescribed them.

The ongoing CORALreef Outcomes trial will provide more data on the cardiovascular benefits of enlicitide. Dr. Navar noted that due to its similar mechanism of action to existing injectable PCSK9 inhibitors, there is reason to believe that enlicitide will also effectively prevent cardiovascular disease.

As healthcare continues to evolve, the integration of oral PCSK9 inhibitors like enlicitide could reshape treatment paradigms for cholesterol management, enhancing patient outcomes and expanding the role of pharmacists in the therapeutic landscape.